Incredibly difficult stock to trade but boy oh boy the long term holders have done ok from this one currently trading 18.80
CUV is not on my trading radar because the daily volume and market depth are usually much to thin for me.
It definitely was a severe reaction to what was basically an overall positive report. It will be interesting to see whether your prediction about Brexit holds true, or whether it's a more temporary glitch.Then they put out a communique about how they were going, all seemed pretty positive until you got to the bit about Brexit and how it may negatively impact the business, splat went the price and I can't see it lifting until Brexit is sorted.
Looking at this company from a fundamental view, it is getting hard to see the price as cheap.PE ratio is nearly 100 after the fall.
The product which provides melatonin to skin that otherwise develops white patches due to a quite rare condition seems a very limited market.
At this stage I would like a medical opinion before investing. Some questions are:How much growth in earnings is there? Do you have up keep taking the product over your whole life?
Are their any competing products?
I'm heavily invested and therefore heavily biased, and a lot of what is said about Clinuvel is based on speculation mostly because it is moving into unknown territory.
How much potential in earnings are there. Potentially a lot. Considering EPP indication alone the earnings are huge when Scenesse is available in Europe and hopefully the US come FDA approval. Nevermind Australia and Japan.
Then we have a similar scenario play out for Vitiligo and XP indications.
Also consider the paediatric dose, and the two other formulations being developed for the last few years with subsidiary Singaporean company Vallaurix.
As far as taking the product over your whole life, with EPP it appears so. 3/4 doses per yr to maintain skin protection. Vitiligo studies haven't seen followup periods sufficient to give an answer. But suggest that the re-pigmentation that does occur is long lasting and regenerative to the melanocytes which lay dormant in the vitligous skin.
It is also a safe drug with a safety profile of many decades, with minor side effects such as nausea and flushing of the face.
For those of us invested in Clinuvel the lack of attention is both flabbergasting and welcomed.
There are competing molecules being developed in the lab. But for all we can tell they are at best 5 years behind, much more likely 10 years +.
That's a long way to goIt's a silly comment to make but this stock just looks like it's going to $100.
I think you need to look no further than what's happening with the broader market, and even more so, with small caps. Most of my shares have fallen together, so CUV falls with the tide. A single stock will nearly always be more volatile that an index, which represents an average of a basket of stocks.People who followed and commented CUV to go to $100, could today's fall be explained other than DJ fall on Friday ?
People who followed and commented CUV to go to $100, could today's fall be explained other than DJ fall on Friday ? Even after more than 10% fall in price, the PE is more than 100. Is it sustainable ? DNH
https://www.asx.com.au/asx/share-price-research/company/CUV
31.000
03 Jun 2019
DAILY-3.490-10.119% DAILY VOLUME198,077
MARKET CAP
1.69bn
BID30.920 OFFER31.120
# SHARES48.96m DIVIDENDS
Most recent 0" class="ng-binding" style="box-sizing: border-box;">2c
Dividend ex-date 21/09/18
Dividend pay date 08/10/18
Franking 0%
Annual dividend yield0.06%
Congrats to any holders, nice X'mas present that has arrived earlySpeechless !!!!!… etc etc
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?